Neil Charter
9 Papers
13 Citations
Neil Charter is an academic researcher. The author has contributed to research in topics: Receptor & Leukemia. The author has an hindex of 4, co-authored 9 publications.
Chat about Author
Papers
Abstract 4957: The novel imipridone ONC212 highly synergizes with the BCL-2 inhibitor ABT-199 in AML and activates orphan receptor GPR132
Takenobu Nii,Jo Ishizawa,Varun V. Prabhu,Vivian Ruvolo,Neel Madhukar,Ran Zhao,Hong Mu,Lauren Heese,Kensuke Kojima,Mathew J. Garnett,Ultan McDermott,Cyril H. Benes,Neil Charter,Sean Deacon,Olivier Elemento,Joshua E. Allen,Wolfgang Oster,Martin Stogniew,Michael Andreeff +18 more
TL;DR: The novel imipridone ONC212 highly synergizes with the BCL-2 inhibitor ABT-199 in AML and activates orphan receptor GPR132 and is investigated in vivo in an aggressive systemic AML xenograft model using OCI-AML3 cells.
8
Abstract 3877: IND-enabling characterization of DRD2/3 imipridone antagonist ONC206 for oncology
Varun V. Prabhu,Abed Rahman Kawakibi,Neel Madhukar,Mathew J. Garnett,Ultan McDermott,Cyril H. Benes,Lakshmi Anantharaman,Neil Charter,Sean Deacon,Alexander VanEngelenburg,Joseph Rucker,Benjamin J. Doranz,Jessica M. Rusert,Robert J. Wechsler-Reya,Olivier Elemento,Martin Stogniew,Wolfgang Oster,Sharon DeMorrow,Sharon DeMorrow,Sharon DeMorrow,Sharon DeMorrow,Sharon DeMorrow,Sharon DeMorrow,R. Benjamin Free,David R. Sibley,Joshua E. Allen +25 more
TL;DR: The results provide rationale for a 50 mg starting ONC206 dose in dose escalation clinical trials in patients with DRD2-dysregulated tumors and suggest a wide therapeutic window for oncology.
5
Exth-43. differentiated pharmacology of the imipridone onc201, the first selective drd2/3 antagonist in clinical neuro-oncology
Neel Madhukar,Varun V. Prabhu,Lakshmi Anantharaman,Chidananda Sulli,Edgar Davidson,Sean Deacon,Rohinton Tarapore,Joseph Rucker,Neil Charter,Benjamin J. Doranz,Wolfgang Oster,Olivier Elemento,R. Benjamin Free,David R. Sibley,Joshua E. Allen +14 more
TL;DR: In this article, the authors identified and characterized a previously unknown binding target of ONC201, a drug target identification platform based on BANDIT, which was used to identify the G-protein coupled receptors (GPCRs) dopamine receptor D2(DRD2) and D3 (DRD3).
Abstract 1155: Potent anti-cancer effects of selective GPR132/G2A agonist imipridone ONC212 in leukemia and lymphoma
Varun V. Prabhu,Neel Madhukar,Rohinton Tarapore,Mathew J. Garnett,Ultan McDermott,Cyril H. Benes,Neil Charter,Sean Deacon,Wolfgang Oster,Michael Andreeff,Olivier Elemento,Martin Stogniew,Joshua E. Allen +12 more
TL;DR: GPR132 agonist ONC212 possesses robust anti-cancer activity in hematological malignancies irrespective of leukemia and lymphoma subtype and provides further validation of the anti- cancer efficacy of the novel imipridone class of small molecules.
2
Ddis-20. imipridone structure activity relationship uncovers onc206 as the next bitopic drd2 antagonist for oncology with differentiated receptor pharmacology
Varun V. Prabhu,Caroline A. Cuoco,Jinkyu Jung,Abed Rahman Kawakibi,Blair K. A. Willette,Marilyn M. Day,Lakshmi Anantharaman,Neil Charter,Joseph Rucker,Benjamin J. Doranz,Wolfgang Oster,Martin Stogniew,Mark R. Gilbert,R. Benjamin Free,David R. Sibley,Joshua E. Allen +15 more
TL;DR: ONC206 emerged as the most selective and potent antagonist forDRD2/DRD3 with complete specificity across human GPCRs and complete DRD2 antagonism and may be poised to address oncogenic DRD 2 monomers or dimers.
1